Micardis Cleared to Help Reduce MI, Stroke, Death


October 19, 2009

Boehringer Ingelheim Pharmaceuticals offers its angiotensin II receptor blocker (ARB) Micardis (telmisartan) tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients age 55 or older at high-risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.

MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998. The FDA also approved a new drug application (NDA) for the combination agent Twynsta (telmisartan/amlodipine) tablets for the treatment of hypertension alone or in combination with other anti-hypertensive agents, or as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals.

TWYNSTA combines the complementary blood pressure lowering effects of telmisartan, the active ingredient in MICARDIS, with the calcium channel blocker (CCB) amlodipine. TWYNSTA is not indicated for cardiovascular risk reduction. The new medicine will be available in pharmacies in November 2009 in the following strengths: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.

For more information: http://us.boehringer-ingelheim.com